Caleb Smith, MD
Hematology & Oncology · Columbia, MONPI 1891284030
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,793 of the $2,220 with a category attached, or 80.8%. It is spread thinly across 35 manufacturers, the largest accounting for just 8.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,782, more than ten times the $67 reported in 2021.
Across 96 payments — averaging $23.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$190
- Sobi, Inc$190
- Gilead$178
- Novartis$164
- Lilly USA, LLC$149
- Johnson & Johnson$128
- plus $1K from 29 others
Across 1 payment — averaging $21,500 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Puma Biotechnology, Inc.$22K
What the payments were for
- Food & beverage$1,79381%
- Education$42619%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 14 | $190 |
| Sobi, Inc | 5 | $190 |
| Gilead(2 entities) | 4 | $178 |
| Novartis | 7 | $164 |
| Lilly USA, LLC | 3 | $149 |
| Johnson & Johnson | 6 | $128 |
| Novo Nordisk | 7 | $117 |
| Seagen Inc. | 1 | $99 |
| AstraZeneca | 5 | $95 |
| GSK | 4 | $82 |
| Daiichi Sankyo Inc. | 3 | $80 |
| Genentech USA, Inc. | 3 | $58 |
| Bristol Myers Squibb | 3 | $56 |
| Incyte Corporation | 3 | $51 |
| Genmab U.S., Inc. | 2 | $44 |
| Legend Biotech USA Inc. | 2 | $42 |
| Octapharma USA, Inc. | 2 | $42 |
| Servier Pharmaceuticals LLC | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Sanofi | 2 | $35 |
| Exelixis Inc. | 1 | $34 |
| Taiho Oncology, Inc. | 2 | $32 |
| Blueprint Medicines Corporation | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Bayer | 1 | $24 |
| Merck | 1 | $23 |
| Beone Medicines USA, Inc. | 1 | $23 |
| Caris MPI, Inc. | 1 | $23 |
| Puma Biotechnology, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $22 |
| Immunocore Limited | 1 | $21 |
| ADC Therapeutics America, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
How this compares
$2,220 in reported general payments places this provider in the 55th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 50 | $461 |
| Dexamethasone | 38 | $453 |
| Prochlorperazine Maleate | 30 | $288 |
| Letrozole | 22 | $240 |
| Olanzapine | 28 | $202 |
| Acyclovir | 20 | $183 |
| Ondansetron Hcl | 31 | $180 |
| Prednisone | 19 | $116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCOlanzapine | $149 | $20228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in Columbia
- David SchlossmanColumbia$1.2M
- Gerhard HildebrandtColumbia$58K
- Umasankar RamadossColumbia$45K
- Liana MakarianColumbia$27K
- Andrew IliffColumbia$25K
- Cherian VergheseColumbia$20K
- Mark TungesvikColumbia$14K
- Vipul BhanderiColumbia$11K
- Elangovan BalakrishnanColumbia$10K
- Ruo Bing XueColumbia$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.